Improving Survival in Stage IV Non-Small Cell Lung Cancer Using Advanced Genomic and Immunotherapy Testing with Usual Care Comparison

What this Trial Is About

Researchers are evaluating the Beating Lung Cancer in Ohio protocol to improve survival in patients with stage IV non-small cell lung cancer NSCLC. This study focuses on assessing immunotherapies and targeted therapies that may extend survival, offer better toxicity profiles than conventional chemotherapy, and impact quality of life. The study includes patients newly diagnosed or diagnosed within the previous year with stage IV NSCLC. Participants are randomized to one of two groups one group receives usual care along with collection of tumor tissue and blood samples for a research repository, while the other group undergoes advanced genomic and immunotherapy testing AGIT including tumor and blood analyses. Additionally, a smoking cessation intervention is offered to current or recent smokers and their household members through either usual care or centralized telephone counseling with decision support. The study also involves correlative studies to identify biomarkers related to immunotherapy response and immune-related adverse events. During the study, participants provide medical records, insurance and billing data, biospecimens, and complete questionnaires through phone, online, or in-person formats. Researchers monitor survival, quality of life using validated questionnaires, smoking cessation outcomes, and the use of genomic testing and targeted therapies. The study duration includes a three-month observation period followed by a 21-month randomized trial phase, with outcomes assessed up to three years. This comprehensive approach helps track the impact of advanced genomic testing and decision support on patient care and survival.

Beating Lung Cancer in Ohio Protocol in Improving Survival in Patients With Stage IV Non-Small Cell Lung Cancer